search
Back to results

Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine

Primary Purpose

Cholera

Status
Completed
Phase
Phase 2
Locations
Bangladesh
Study Type
Interventional
Intervention
Cholvax
Shanchol
Sponsored by
International Centre for Diarrhoeal Disease Research, Bangladesh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cholera focused on measuring cholera vaccine, randomized trial, immunogenicity

Eligibility Criteria

1 Year - 45 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age: 1-45 Years.
  2. Informed consent from study participants and guardian in case of children (1-17 years) and assent from children aged 11-17 years.
  3. Participation in the study at least for next 6 months
  4. Considered healthy as per medical judgment of the investigator

Exclusion Criteria:

  1. Suffering from diarrhea or abdominal pain or vomiting in the past 24 hours or diarrhea lasting for more than 2 weeks in the past 6 months
  2. History of taking oral cholera vaccine and history of confirmed cholera.
  3. History of taking any other live or killed enteric vaccine in the last 8 weeks.
  4. History of anaphylaxis or serious vaccine reaction.
  5. Currently use of any immunosuppressive or immune-modifying drugs. 6.100.4 0 F (38℃) or higher body temperature measured prior to investigational product dosing.

7.Receipt of blood or blood products or parenteral immunoglobulin preparation in the past 3 months.

8.Currently on antimicrobial therapy. 9.Severe malnutrition or chornic disease based on the jugement of the investigator.

10.Stool sample at screening positive for V. cholerae. 11.Pregnant women or plans to become pregnant during the study period .

Sites / Locations

  • International Centre for Diarrhoeal Disease Research, Bangladesh

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

cholvax

shanchol

Arm Description

Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.

The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.

Outcomes

Primary Outcome Measures

Number of participants with vaccine related reactogenicity as assessed by study personnel
Number of reactogenecity events will be compared between test group and comparator group.
Number of participants with solicited adverse events as assessed by study personnel
Number of solicited adverse events observed after each dose of vaccination assessed by study personnel through home visit and will be compared between test group and comparator group
Number of participants with unsolicited adverse event including serious adverse event as assessed by study physician
Number of unsolicited adverse events including serious adverse event observed after each dose of vaccination assessed by study personnel through home visit and will be compared between test group and comparator group
Number of participants showing seroconversion against sero group V. cholerae O1
Proportion of participants showing sero-conversion against V. cholerae O1, upon vaccination Cholvax being tested in comparison with ShancholTM.

Secondary Outcome Measures

Number of participants showing seroconversion against sero group V. cholerae O139
Proportion of participants showing sero-conversion against serogroup V. cholerae O139 upon vaccination with Cholvax in comparison with ShancholTM will be measured and compared between test and comparator group Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) as measured by anti-V. cholerae O1 antibody titer at day 7 and day 21 after the first dose of investigational product dose as compared to baseline (day0). Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) as measured by anti-V. cholerae O139 antibody titer at day 7 and day 21 after the first dose of investigational product dose as compared to baseline (day 0).

Full Information

First Posted
April 7, 2016
Last Updated
June 15, 2017
Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
International Vaccine Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02742558
Brief Title
Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine
Official Title
A Randomized Observer Blinded Controlled Non Inferiority Trial to Evaluate the Safety and Immunogenicity of Locally Manufactured Inactivated Bivalent Whole Cell-oral Cholera Vaccine (WC-OCV) 'Cholvax' in Bangladeshi Healthy Adults and Children
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
June 2017 (Actual)
Study Completion Date
June 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
International Vaccine Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate and compare the safety and immunogenicity of the Cholvax with ShancholTM, Investigators will conduct a clinical trial study Bangladeshi healthy adults and children. Cholvax is locally produced orally administered whole cell inactivated bivalent cholera vaccine. Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the oral cholera vaccine, Cholvax with technological support from International Vaccine Institute (IVI). Cholvax meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation. By this transfer of technology, it expected that the vaccine will become available for use in public health programs in Bangladesh and in the future in other cholera-affected countries in Asia and Africa to control endemic cholera, as well as to help control large-scale epidemics and outbreaks. Investigators will also evaluate and compare the safety and immunogenicity of 3 Cholvax lots (lot-to-lot consistency).
Detailed Description
Background : Cholera continues to be a major cause of morbidity and mortality in low-income countries including Bangladesh. It is estimated that there are at least 300,000 severe cases and over 4,500 deaths in Bangladesh each year1. The overall morbidity for cholera remains high. A global stockpile of OCV has been created by WHO in 2013 for epidemic and outbreak settings2. However, the global demand for the vaccine far exceeds the present supply for both epidemic and also endemic settings3. It can be envisioned that local production of an affordable OCV for high risk population in endemic settings will improve the present scenario in Bangladesh and other countries. Knowledge gap: The WHO recommends OCV for use in both endemic and epidemic cholera settings4. At present there are two vaccines that are WHO prequalified. These include Dukoral which is registered in Bangladesh and in over 50 countries. However, the disadvantage of use of Dukoral is that its current price it is expensive for Bangladesh and other developing countries. In addition, the need for buffer to formulate the vaccine makes it less fieldable for mass vaccination programs. Another whole cell killed OCV, ShancholTM, which is WHO prequalified, is based on similar bacterial components as Dukoral and licensed in India but not in Bangladesh. Although this vaccine is relatively affordable it may not be sufficiently cost effective for the Government of Bangladesh to implement it in our poor endemic settings. At present, the vaccine is in short supply and will not be able to meet the global demands. In order to increase supply of OCV and make the vaccine more affordable, a locally manufactured killed bivalent whole cell-oral cholera vaccine Cholvax is now available. The present study will evaluate the safety and immunogenicity of Cholvax as a test vaccine using Shanchol TM as the comparator vaccine in a non inferiority trial design. Relevance: The study of this locally manufactured OCV, Cholvax among children and adults will be able to give us information regarding the safety and immunogenicity of the vaccine. Based on this information, it can be anticipated that regulatory requirements as well as licensure of the vaccine will be initiated in Bangladesh. This will pave the way forward for the future approval by WHO and for its global use. The introduction of Cholvax in endemic settings, seasonal outbreak as well as in the EPI program of the country in the future can be expected based on the study results; initiatives and plans can be made to introduce this locally produced vaccine in Bangladesh at an affordable cost and in the future globally. Hypothesis (if any): Locally produced orally administered whole cell inactivated bivalent cholera vaccine, Cholvax is non inferior or at least as safe and immunogenic in adults and children in Bangladesh as compared to Shanchol TM. Objectives: The objectives of this study are- i. To evaluate and compare the safety and immunogenicity of the Cholvax with ShancholTM ii. To evaluate the safety and immunogenicity of Cholvax in healthy adults and children in Dhaka. iii. To evaluate and compare the safety and immunogenicity of 3 Cholvax lots (lot-to-lot consistency) Methods: This will be a randomized, observer blinded and comparative study on a total of 2052 healthy participants, 1026 Cholvax (Test Group) and 1026 ShancholTM (Comparator Group) recipients. There will be three age cohort arms in each test and comparator group which will consist of 219 participants for age 1-5Yrs, 373 participants for age 6-17Yrs and 434 for Age 18-45Yrs, with a total of 2052 participants. Participants will receive either Cholvax or ShancholTM two doses 14 days apart. Each age cohort of the study (Cohort I onwards) will be completed and based on the development, and progress, the next age cohort will be initiated. If the vaccine is found to be safe in the adults it will be tested in the children, 6-17 years of age and followed by the younger age group 1-5 years of age. The results will be presented to the Data Safety Monitoring Board after completing the 28-day safety surveillance part of each age cohort of the study and before proceeding to the next study age cohort.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholera
Keywords
cholera vaccine, randomized trial, immunogenicity

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
2052 (Actual)

8. Arms, Groups, and Interventions

Arm Title
cholvax
Arm Type
Experimental
Arm Description
Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
Arm Title
shanchol
Arm Type
Active Comparator
Arm Description
The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
Intervention Type
Biological
Intervention Name(s)
Cholvax
Intervention Description
Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
Intervention Type
Biological
Intervention Name(s)
Shanchol
Intervention Description
The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
Primary Outcome Measure Information:
Title
Number of participants with vaccine related reactogenicity as assessed by study personnel
Description
Number of reactogenecity events will be compared between test group and comparator group.
Time Frame
Within 30 minutes after administration of vaccine
Title
Number of participants with solicited adverse events as assessed by study personnel
Description
Number of solicited adverse events observed after each dose of vaccination assessed by study personnel through home visit and will be compared between test group and comparator group
Time Frame
Within 7 days after administration of vaccine
Title
Number of participants with unsolicited adverse event including serious adverse event as assessed by study physician
Description
Number of unsolicited adverse events including serious adverse event observed after each dose of vaccination assessed by study personnel through home visit and will be compared between test group and comparator group
Time Frame
Within 6 months after administration of vaccine
Title
Number of participants showing seroconversion against sero group V. cholerae O1
Description
Proportion of participants showing sero-conversion against V. cholerae O1, upon vaccination Cholvax being tested in comparison with ShancholTM.
Time Frame
7 days after administration of vaccine
Secondary Outcome Measure Information:
Title
Number of participants showing seroconversion against sero group V. cholerae O139
Description
Proportion of participants showing sero-conversion against serogroup V. cholerae O139 upon vaccination with Cholvax in comparison with ShancholTM will be measured and compared between test and comparator group Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) as measured by anti-V. cholerae O1 antibody titer at day 7 and day 21 after the first dose of investigational product dose as compared to baseline (day0). Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) as measured by anti-V. cholerae O139 antibody titer at day 7 and day 21 after the first dose of investigational product dose as compared to baseline (day 0).
Time Frame
7 days after administration of vaccine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age: 1-45 Years. Informed consent from study participants and guardian in case of children (1-17 years) and assent from children aged 11-17 years. Participation in the study at least for next 6 months Considered healthy as per medical judgment of the investigator Exclusion Criteria: Suffering from diarrhea or abdominal pain or vomiting in the past 24 hours or diarrhea lasting for more than 2 weeks in the past 6 months History of taking oral cholera vaccine and history of confirmed cholera. History of taking any other live or killed enteric vaccine in the last 8 weeks. History of anaphylaxis or serious vaccine reaction. Currently use of any immunosuppressive or immune-modifying drugs. 6.100.4 0 F (38℃) or higher body temperature measured prior to investigational product dosing. 7.Receipt of blood or blood products or parenteral immunoglobulin preparation in the past 3 months. 8.Currently on antimicrobial therapy. 9.Severe malnutrition or chornic disease based on the jugement of the investigator. 10.Stool sample at screening positive for V. cholerae. 11.Pregnant women or plans to become pregnant during the study period .
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Firdausi Qadri, Dr.
Organizational Affiliation
International Centre for Diiarrhoeal Disease Research, Bangladesh
Official's Role
Study Director
Facility Information:
Facility Name
International Centre for Diarrhoeal Disease Research, Bangladesh
City
Dhaka
ZIP/Postal Code
1212
Country
Bangladesh

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be shared with International Vaccine Institute
Citations:
PubMed Identifier
22461716
Citation
Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J. The global burden of cholera. Bull World Health Organ. 2012 Mar 1;90(3):209-218A. doi: 10.2471/BLT.11.093427. Epub 2012 Jan 24.
Results Reference
result
PubMed Identifier
24101640
Citation
Maskery B, DeRoeck D, Levin A, Kim YE, Wierzba TF, Clemens JD. Strategy, demand, management, and costs of an international cholera vaccine stockpile. J Infect Dis. 2013 Nov 1;208 Suppl 1:S15-22. doi: 10.1093/infdis/jit233.
Results Reference
result
PubMed Identifier
21907255
Citation
Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine. 2011 Oct 26;29(46):8285-92. doi: 10.1016/j.vaccine.2011.08.108. Epub 2011 Sep 9.
Results Reference
result

Learn more about this trial

Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine

We'll reach out to this number within 24 hrs